AccuStem Sciences, Inc. (ACUT)
OTCMKTS · Delayed Price · Currency is USD
0.280
0.00 (0.00%)
At close: Apr 24, 2026

AccuStem Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Selling, General & Admin
1.481.371.913.480.6
Upgrade
Research & Development
0.280.140.140.270.07
Upgrade
Operating Expenses
1.761.512.053.750.67
Upgrade
Operating Income
-1.76-1.51-2.05-3.75-0.67
Upgrade
Pretax Income
-1.76-1.51-2.05-3.75-0.67
Upgrade
Net Income
-1.76-1.51-2.05-3.75-0.67
Upgrade
Net Income to Common
-1.76-1.51-2.05-3.75-0.67
Upgrade
Shares Outstanding (Basic)
1511111110
Upgrade
Shares Outstanding (Diluted)
1511111110
Upgrade
Shares Change (YoY)
33.21%0.78%3.00%10.17%-
Upgrade
EPS (Basic)
-0.12-0.13-0.18-0.34-0.07
Upgrade
EPS (Diluted)
-0.12-0.13-0.18-0.34-0.07
Upgrade
Free Cash Flow
-0.85-0.66-1.62-1.82-
Upgrade
Free Cash Flow Per Share
-0.06-0.06-0.14-0.17-
Upgrade
EBITDA
-1.76-1.5-2.05-3.74-
Upgrade
D&A For EBITDA
0000-
Upgrade
EBIT
-1.76-1.51-2.05-3.75-0.67
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.